1. Introduction {#sec1-ijms-20-05696}
===============

It is well documented that the large-scale use of chemical antimicrobials and antibiotics causes resistance in pathogenic microorganisms. Bacteria rapidly mutate and adapt in response to new hostile environments \[[@B1-ijms-20-05696]\]. Therefore, it is not a wise solution that the use of these antimicrobials be kept to a minimum or until pathogens are halted. Recently, natural antimicrobials from aromatic plants have attracted attention as alternatives to chemical ones \[[@B2-ijms-20-05696]\]. Essential oils (EOs), the secondary metabolites of aromatic plants, are used to prevent bacterial infections due to their prominent antibacterial activity and quorum sensing (QS) inhibition. They are also safe and nontoxic compounds, meeting the requirements for green antibacterial agents \[[@B3-ijms-20-05696]\].

QS is a cell-density-dependent mechanism used by bacteria to regulate gene expression \[[@B4-ijms-20-05696]\]. Bacteria release autoinducers (AIs) or signals that realize cell-to-cell communication, and AIs have been identified as oligopeptides and *N*-acyl-homoserine lactones (AHLs) in Gram-positive and Gram-negative bacteria, respectively \[[@B5-ijms-20-05696]\]. Numerous studies have shown that bacteria rely on QS systems to orchestrate the synchronous secretion of virulence factors (VFs) and biofilm formation \[[@B6-ijms-20-05696]\]. Potential QS inhibitors (QSIs) can reduce the bacterial pathogenicity and target bacterial QS systems rather than killing cells, which can reduce or slow the selective pressure for developing resistance \[[@B7-ijms-20-05696],[@B8-ijms-20-05696]\]. *Chromobacterium violaceum* ATCC31532, a well-documented Gram-negative bacterium, has been used widely in screening QS inhibitors and in researching the QS inhibitory mechanism, due to its visible violacein \[[@B9-ijms-20-05696]\] and clear QS regulatory system. *N*-hexanoyl-[l]{.smallcaps}-homoserine lactone (C6-HSL), which is modulated by the *cviI* gene, binds to the transcriptional regulator to regulate biofilm formation, swarming movement, and the secretion of virulence factors such as violacein and exopolysaccharide (EPS) \[[@B10-ijms-20-05696]\]. It was previously found that sub-minimal inhibitory concentration (sub-MIC) EO levels of green cardamom, rose, clove, and chamomile are capable of blocking the network in *C. violaceum* \[[@B11-ijms-20-05696],[@B12-ijms-20-05696]\]. In this light, plant EOs are expected to be emerging QSIs to attenuate the virulence of pathogens and control bacterial infections and drug resistance.

*Melaleuca* is a genus of plants in the Myrtle family Myrtaceae, mainly in Australia, and several species have been introduced and cultivated in China \[[@B13-ijms-20-05696]\]. Species from this genus are known to be good sources of antibacterial agents and medicinal materials. For example, "tea tree oil" derived from *M. alternifolia* is used in food processing to extend product shelf life \[[@B14-ijms-20-05696]\]. *Melaleuca bracteata* is popularly exploited as an ornamental plant and is well known for its aromatic properties, as well as its vast medicinal properties. It is used to treat heart attack, stroke, infected wounds, skin disorders, and fungal infection. Furthermore, *M. bracteata* is also used to aid in stimulating glandular secretions and to reduce congestion in the veins, and its leaves constitute a component of an anti-HIV concoction. In addition, the stem bark extract of *M. bracteata* possesses antisecretory and antiulcerogenic activities \[[@B15-ijms-20-05696]\]. The antibacterial and antioxidant activity of *M. bracteata* EO has recently been reported \[[@B16-ijms-20-05696],[@B17-ijms-20-05696]\], but its anti-QS ability has never been described. Thus, we tested its antibacterial ability against pathogenic bacteria and anti-QS activity against *C. violaceum* ATCC31532 in this work, providing a theoretical basis for the development of *M. bracteata* EO as an antibacterial agent and QS inhibitor to prevent and control bacterial contamination.

2. Results {#sec2-ijms-20-05696}
==========

2.1. Analysis of the Components in *M. bracteata* EO by GC-MS {#sec2dot1-ijms-20-05696}
-------------------------------------------------------------

A total ion flow chromatogram of the *M. bracteata* EO analyzed by GC-MS is shown in [Figure 1](#ijms-20-05696-f001){ref-type="fig"}. The correlations of the peak area normalization method with the mass spectrometry database were determined to qualitatively and quantitatively analyze the components of the EO. [Table 1](#ijms-20-05696-t001){ref-type="table"} shows that 29 components were identified from the *M. bracteata* EO, accounting for 96.49% of the total contents, among which methyleugenol displayed the largest proportion, up to 90.46%, followed by methyl trans-cinnamate (relative content of 4.25%), and the relative content of other components was less than 1%.

2.2. Determination of the Antimicrobial Activity and MIC of *M. bracteata* EO {#sec2dot2-ijms-20-05696}
-----------------------------------------------------------------------------

The antimicrobial activities of the *M. bracteata* EO were tested against the common pathogens *D. dadantii* Onc5, *S. aureus* ATCC25933, *Pseudomonas* spp., *E. coli* ATCC25922, *S. marcescens* MG1, *P. aeruginosa* PAO1, and *C. violaceum* ATCC31532 using the plate perforation method. *M. bracteata* EO exhibited an effective concentration-dependent inhibitory effect against all tested bacteria. *M. bracteata* EO showed stronger inhibition against *S. aureus* ATCC25933 and *S. marcescens* MG1 with higher inhibition ability (15.28 ± 1.083 mm and 14.11 ± 0.789 mm, respectively) than other test bacteria at the concentration of 80‰. *M. bracteata* EO exhibited antibacterial activity against *D. dadantii* Onc5, *P. aeruginosa* PAO1, *E. coli* ATCC25922, *Pseudomonas* spp., and *C. violaceum* ATCC31532 with inhibition zone diameters of 11.89 ± 0.246 mm, 10.47 ± 0.186 mm, 11.38 ± 0.286 mm, 13.42 ± 0.715 mm, and 11.55 ± 0.34 mm, respectively ([Table 2](#ijms-20-05696-t002){ref-type="table"}).

The MIC of *M. bracteata* EO was assessed for all test pathogens using the double dilution method with concentrations varying from 80‰ to 0.625‰. The MIC of *M. bracteata* EO was 2.5‰ for *S. aureus* ATCC25933 and *S. marcescens* MG1, 5‰ for *Pseudomonas* spp., 10‰ for *D. dadantii* Onc5, *E. coli* ATCC25922, and *C. violaceum* ATCC31532, and 20‰ for *P. aeruginosa* PAO1 ([Table 2](#ijms-20-05696-t002){ref-type="table"}).

Collectively, the results indicated that *S. aureus* ATCC25933 and *S. marcescens* MG1 had higher sensitivity to *M. bracteata* EO, while *P. aeruginosa* PAO1 showed the strongest resistance to *M. bracteata* EO.

2.3. Quorum Sensing Inhibition (QSI) assays of *M. bracteata* EO {#sec2dot3-ijms-20-05696}
----------------------------------------------------------------

The zone of non-purple pigment on agar plates and the extent of the inhibition of purple pigment in *C. violaceum* CV026 by *M. bracteata* EO were observed as shown in [Figure 2](#ijms-20-05696-f002){ref-type="fig"}, indicating that *M. bracteata* EO showed good inhibition for the QS-mediated violacein production of CV026. Hence, in the present study, *M. bracteata* EO at sub-MICs (5‰, 2.5‰, 1.25‰, and 0.625‰) was used for the further experiments.

2.4. Growth Curve {#sec2dot4-ijms-20-05696}
-----------------

To confirm the non-antibacterial activity of *M. bracteata* EO at sub-MICs (5‰, 2.5‰, 1.25‰, and 0.625‰), the activities of *C. violaceum* treated with or without different concentrations of *M. bracteata* EO were determined for 0--72 h. The growth curve showed that *C. violaceum* treated with *M. bracteata* EO at sub-MICs began to enter the logarithmic phase later than the control. Nevertheless, the growth of *C. violaceum* did not differ between the control and treated groups in the stationary phase (\>12 h) ([Figure 3](#ijms-20-05696-f003){ref-type="fig"}). These results revealed that *M. bracteata* EO was inefficient at inhibiting growth under the test conditions. We therefore assessed the specific effect of *M. bracteata* EO at sub-MICs (5‰, 2.5‰, 1.25‰, and 0.625‰) on QS in *C. violaceum*.

2.5. Determination of Violacein {#sec2dot5-ijms-20-05696}
-------------------------------

Violacein is the important metabolite of *C. violaceum* which is regulated by the QS system \[[@B18-ijms-20-05696]\]. Therefore, we detected the effect of *M. bracteata* EO on the violacein in *C. violaceum*. In the quantitative assay, violacein inhibition reached a maximum of 85.47% in *C. violaceum* when treated with *M. bracteata* EO at 5‰ (the highest tested concentration) ([Figure 4](#ijms-20-05696-f004){ref-type="fig"}).

2.6. Biofilm Determination {#sec2dot6-ijms-20-05696}
--------------------------

The quantitative biofilm assay demonstrated that treatment with *M. bracteata* EO (5‰, 2.5‰, 1.25‰, and 0.625‰) inhibited the biofilm biomass of *C. violaceum* in a concentration-dependent manner, and the inhibition of biofilm biomass were 75.56%, 75.03%, 58.16%, and 20.2%, respectively ([Figure 5](#ijms-20-05696-f005){ref-type="fig"}A). In addition, *M. bracteata* EO was found to be very effective in inhibiting biofilm formation of *C. violaceum* based on observations by light microscope ([Figure 5](#ijms-20-05696-f005){ref-type="fig"}B).

2.7. Swarming Motility Assay {#sec2dot7-ijms-20-05696}
----------------------------

Swarming migration plays an important role in QS-regulated biofilm formation in pathogens \[[@B19-ijms-20-05696],[@B20-ijms-20-05696]\]. An effort was made to examine the anti-QS potential of *M. bracteata* EO against swarming motility in *C. violaceum*. The results showed that *M. bracteata* EO disturbed the swarming behavior of *C. violaceum*, and the maximum inhibition was recorded at the highest concentration (5‰) ([Figure 6](#ijms-20-05696-f006){ref-type="fig"}).

2.8. Detection of the Production of C6-HSL Signal Molecules {#sec2dot8-ijms-20-05696}
-----------------------------------------------------------

The C6-HSL production was measured through a well-diffusion assay using CVO26 as the monitor strain, and the concentration of C6-HSL extracts was estimated by measuring the diameter of the violacein induced zone. The extracts from *C. violaceum* treated with or without *M. bracteata* EO (5‰, 2.5‰, 1.25‰, and 0.625‰) suggested that *M. bracteata* EO is able to reduce the C6-HSL production in a concentration-dependent manner ([Figure S1](#app1-ijms-20-05696){ref-type="app"}).

To verify the biosensor screening results, the C6-HSL extracts were analyzed quantitatively by GC technology. According to the retention time and the standard curve, the concentration of C6-HSL in the extracted samples was calculated ([Figure S2](#app1-ijms-20-05696){ref-type="app"}). In agreement with observations in the CV026 biosensor, the concentration of C6-HSL in the treated groups decreased significantly compared with the control. In addition, the concentrations in the control group and the treatment group (5‰, 2.5‰, 1.25‰, and 0.625‰ *M. bracteata* EO) were 0.38, 0.08, 0.12, 0.18, and 0.22 mg/mL, respectively ([Figure 7](#ijms-20-05696-f007){ref-type="fig"}A and [Figure S3](#app1-ijms-20-05696){ref-type="app"}). Our data confirmed that *M. bracteata* EO was able to repress C6-HSL production in *C. violaceum*, which resulted in the attenuation of bacterial virulence.

The capacity of *M. bracteata* EO to target C6-HSL directly was determined by adding exogenous C6-HSL to LB broth supplemented with *M. bracteata* EO extracts at the highest tested concentration of 5‰. Compared to the control, the extract had no significant effect at 6 h, and then a significant drop in the C6-HSL content was observed with the increase in incubation time (at 12 h and 24 h) ([Figure 7](#ijms-20-05696-f007){ref-type="fig"}B and [Figure S4](#app1-ijms-20-05696){ref-type="app"}). These data suggest that *M. bracteata* EO can directly degrade C6-HSL.

In addition, the C6-HSL extracts from *C. violaceum* CV026 treated with *M. bracteata* EO (5‰, 2.5‰, 1.25‰, and 0.625‰) showed that the consumption of exogenous C6-HSL with *M. bracteata* EO treatment was lower than that of the control. Among the exogenous C6-HSL with the lowest consumption was at the highest tested concentration of 5‰, independent of a direct effect on growth ([Figure 7](#ijms-20-05696-f007){ref-type="fig"}C and [Figure S5](#app1-ijms-20-05696){ref-type="app"}). The results indicate that *M. bracteata* EO may be able to interact with the cviR protein.

Collectively, we speculated that *M. bracteata* EO not only degraded the C6-HSL directly and inhibited C6-HSL production, but also interacted with the cviR protein.

2.9. *M. bracteata* EO Reduced the Expression of the QS-Related Genes {#sec2dot9-ijms-20-05696}
---------------------------------------------------------------------

*cviI*/*cviR* are important regulatory factors in the QS system of *C. violaceum* \[[@B18-ijms-20-05696]\]. Accordingly, we assessed the effects of *M. bracteata* EO on the main regulatory factors *cviI* and *cviR* in *C. violaceum* ATCC 31532 by RT-qPCR. As expected, the expression of *cviI* and *cviR* revealed a dose-dependent downregulation in response to *M. bracteata* EO (5‰, 2.5‰, 1.25‰, and 0.625‰) in comparison with the control ([Figure 8](#ijms-20-05696-f008){ref-type="fig"}). Furthermore, we detected the effect of methyleugenol (ME) on the expression of important virulence factors, including violacein production (via *vioA--E*), biofilm formation (via *hmsNRHF*), and elastase production (via *lasA* and *lasB*) \[[@B21-ijms-20-05696]\]. These genes are downstream of the QS cascade and controlled by the QS system. In the presence of *M. bracteata* EO, the expression of *vioA, vioB, vioC, vioD, vioE, hmsN, hmsR, lasA*, and *lasB* were clearly suppressed relative to the control group ([Figure 9](#ijms-20-05696-f009){ref-type="fig"}). However, the expression of *hmsH* and *hmsF* was not affected by *M. bracteata* EO ([Figure S6](#app1-ijms-20-05696){ref-type="app"}).

Studies have revealed that pilus (*pilE1--3*) and cyanide production (*hcnA--C*) were associated with the QS system in *C. violaceum* \[[@B22-ijms-20-05696]\]. Considering our observation that the *cviI*/*cviR* system was significantly suppressed in response to EO, we decided to monitor the change in *pilE1*--3 and *hcnA*--*C*. Although other genes were significantly repressed by *M. bracteata* EO, *hcnA*, *hcnC,* and *pilE2* were not ([Figure 9](#ijms-20-05696-f009){ref-type="fig"} and [Figure S6](#app1-ijms-20-05696){ref-type="app"}). It is possible that these genes were not directly or independently controlled by the QS system. Collectively, our data suggest that *M. bracteata* EO can be used to inhibit the expression of key virulence genes of *C. violaceum*, independent of a direct effect on growth rate.

3. Discussion {#sec3-ijms-20-05696}
=============

A variety of aromatic plants have been reported to have antibacterial activities and anti-quorum sensing activities \[[@B7-ijms-20-05696],[@B23-ijms-20-05696]\]. *M. bracteata*, as an excellent medicinal aromatic plant with colorful leaves, has great development and utilization value. In this paper, we evaluated the antimicrobial activity of *M. bracteata* EO against seven pathogens, and its potential anti-QS activity was detected for the first time with *C. violaceum* ATCC31532.

*M. bracteata* EO was capable of inhibiting pathogens, including: *D. dadantii* Onc5, *S. aureus* ATCC25933, *Pseudomonas* spp., *E. coli* ATCC25922, *S. marcescens* MG1, *P. aeruginosa* PAO1, and *C. violaceum* ATCC31532. Among them, *D. dadantii* Onc5 and *Pseudomonas* spp. are pathogenic bacteria that cause plant soft rot. The results showed that *M. bracteata* EO had stronger inhibition against *S. aureus* ATCC25933 and *S. marcescens* MG1, and *P. aeruginosa* PAO1 was generally more resistant than the other organisms tested in this paper, which were well-matched with the MIC results. A study by Siddique et al. \[[@B16-ijms-20-05696]\] showed that *M. bracteata* EO exhibited antimicrobial activities against pathogens including Gram-positive (*Bacillus subtilis* subsp *spizizenii*, *Staphylococcus aureus*) and Gram-negative bacteria (*Enterobacter aerogenes*, *Escherichia coli*, *Klebsiella pneumonia*, *Pseudomonas aeruginosa,* and *Salmonella enterica*). Collectively, *M. bracteata* EO has the potential to act as a natural antibacterial agent due to its outstanding and broad-spectrum antimicrobial activity. Some antimicrobial agents with broad-spectrum antimicrobial activity have QS inhibitory activities under sub-MICs \[[@B23-ijms-20-05696],[@B24-ijms-20-05696]\]. Thus, we are very interested in whether *M. bracteata* EO is capable of suppressing bacterial pathogenicity based on interfering with QS systems instead of having a direct effect on growth.

In the present study, we have systematically studied the inhibitory effect of *M. bracteata* EO (sub-MICs) on the QS system of *C. violaceum* from the QS phenotype and at the molecular level. We detected the QS inhibitory potential of *M. bracteata* EO based on its ability to inhibit the production of AHL-dependent virulence factors such as violacein in *C. violaceum*. It has previously been confirmed that the compound, which has the ability to inhibit violacein production without influencing the growth of *C. violaceum*, is considered to be a promising QS inhibitor \[[@B25-ijms-20-05696],[@B26-ijms-20-05696]\]. Biofilm formation plays an important role in bacterial pathogenicity and decreases drug sensitivity. Thus, interfering with biofilm formation might be a preferable and convenient way to attenuate the virulence of disease pathogens as well as drug resistance \[[@B27-ijms-20-05696],[@B28-ijms-20-05696]\]. A biofilm detection assay showed that *M. bracteata* EO not only reduced the biofilm biomass but also influenced the colony formation, as evidenced by the light microscope images in [Figure 5](#ijms-20-05696-f005){ref-type="fig"}B. The inhibition response of natural products as found in our study is also supported by the findings on EO of *Cuminum cyminum* \[[@B29-ijms-20-05696]\] and *Mentha piperita* \[[@B30-ijms-20-05696]\], which also influenced the biofilm biomass and formation of *Pseudomonas aeruginosa*, *C. violaceum,* and *Aeromonas hydrophila*. Swarming involves the differentiation of vegetative cells into hyper-flagellated swarm cells that undergo rapid and coordinated population migration across solid surfaces, and swimming and swarming behavior essentially determine the biofilm formation \[[@B20-ijms-20-05696]\]. Thus, the inhibition of swarming motility by *M. bracteata* EO partially accounted for the reduction in the biofilm biomass and disruption of biofilm architecture in *C. violaceum*. We next employed RT-qPCR to evaluate the expression of QS-regulated genes (*vioA-E*, *hmsNRHF*) in *C. violaceum*. The RT-qPCR results did not correlate well with biofilm results. The expression of *hmsHF* did not decrease in response to *M. bracteata* EO in a concentration-dependent manner compared with that of control. The above data indicate that biofilm formation is a sophisticated process and that QS is a vital regulatory mechanism for biofilm formation, but not the only one.

According to the working model of QS regulation, the LuxR receptors are unstable, and rapidly degraded at low AI concentrations. As the cell density increases, the accumulated AI binds the LuxR-type receptor, leading to stabilization of the LuxR--AI complex, which subsequently binds DNA in promoters, driving genes regulated by QS \[[@B31-ijms-20-05696]\]. Thus, QS quenching can be achieved either by interruption of AI signal generation, inhibition of AI signal dissemination, or inhibition of AHL signal reception \[[@B32-ijms-20-05696]\]. The reduction in C6-HSL concentrations in *C. violaceum* culture treated with *M. bracteata* EO could be the result of either (1) inhibition of cell growth, (2) degradation of C6-HSL, or (3) inhibition of the C6-HSL production. With regard to the first hypothesis, it was observed that the growth tendencies of *C. violaceum* treated and untreated with *M. bracteata* EO were similar, without obvious differences after 12 h. The second hypothesis refers to the potential degradation of C6-HSL by *M. bracteata* EO. The quantification of C6-HSL in inoculated broth treated with *M. bracteata* EO (the highest tested concentration of 5‰) revealed that *M. bracteata* EO was able to directly degrade C6-HSL ([Figure 7](#ijms-20-05696-f007){ref-type="fig"}B). Regarding the third hypothesis, a dose-dependent reduction of C6-HSL production in *C. violaceum* showed that *M. bracteata* EO interfered with the accumulation of C6-HSL ([Figure 7](#ijms-20-05696-f007){ref-type="fig"}A, [Figure S2](#app1-ijms-20-05696){ref-type="app"}). When it is taken into account that C6-HSL degradation was approximately 34.44% in the presence of 5‰ *M. bracteata* EO for 12 h ([Figure 7](#ijms-20-05696-f007){ref-type="fig"}B), the inhibition of QS by *M. bracteata* EO could attributed to its capacity to inhibit C6-HSL production.

Moreover, the antagonists targeting the LuxR receptors also have huge potential for anti-QS development. Chloro thiolactone (CTL) and chloro lactone (CL) were shown to be cviR antagonists that prevent cviR from binding the promoter DNA of regulated genes \[[@B33-ijms-20-05696]\]. Interestingly, we found that the consumption of exogenous C6-HSL was lowest in CV026 upon treatment with *M. bracteata* EO (at the highest tested concentration of 5‰); we inferred that *M. bracteata* EO can interact with cviR. Collectively, the findings in this work strongly support that *M. bracteata* EO acts through the QS machinery to inhibit specific virulence determinants in *C. violaceum*. The possibility of QS suppression by *M. bracteata* EO consists mainly of interactions with cviR and/or cviI proteins, directly resulting in the suppression of C6-HSL production, and is partially related to the degradation of C6-HSL production.

This finding is consistent with previous studies \[[@B34-ijms-20-05696]\] which indicated that methyleugenol (ME) was the major constituent of *M. bracteata* EO, with a relative content of up to 90.46%. A study by Packiavathy et al. showed that ME exhibited violacein inhibition without growth inhibition \[[@B29-ijms-20-05696]\]. Consistent with the above findings, ME also exhibited QSI activity toward the biosensor CV026 in the present study ([Figure S7](#app1-ijms-20-05696){ref-type="app"}). Thus, we inferred that ME may play a leading role in the suppression of the QS system by *M. bracteata* EO. However, more work is clearly required in order to ascertain the exact binding site and molecular mechanism of action.

4. Materials and Methods {#sec4-ijms-20-05696}
========================

4.1. Essential Oil, Bacterial Strains, Medium, and Growth Conditions {#sec4dot1-ijms-20-05696}
--------------------------------------------------------------------

The leaves of *M. bracteata* were collected from Fujian Agriculture and Forestry University (Fujian, China). Essential oil (EO) was extracted by steam distillation and then stored at −20 °C.

The microorganisms researched in this study were *Dickeya dadantii* Onc5, *Staphylococcus aureus* ATCC25933, *Pseudomonas* spp. (isolated from *Capsicum annuum* L), *Escherichia coli* ATCC25922, *Serratia marcescens* MG1, *Pseudomonas aeruginosa* PAO1, *Chromobacterium violaceum* ATCC31532, and *Chromobacterium violaceum* CV026, which were stocked in our laboratory. All tested bacteria were incubated in LB broth and grown under conditions of 30 °C, 150 rpm, and 12 h. The swarming motility medium consisted of 1% tryptone, 0.5% NaCl, 0.5% agar, and 0.5% [d]{.smallcaps}-glucose. *N*-Hexanoyl-[l]{.smallcaps}-homoserine lactone (C6-HSL) was purchased from Sigma-Aldrich (Shanghai, China). *n*-Alkanes (C8--C20) standard solution was purchased from Fluka (Shanghai, China).

4.2. Determination of Components of M. bracteata EO by GC-MS {#sec4dot2-ijms-20-05696}
------------------------------------------------------------

The *M. bracteata* EO was subjected to GC-MS analysis using a GC (Clarus^®^680) equipped with a mass-selective detector (SQ8T) in electronic ionization (EI) mode and Turbomass Ver 6.1.0 software (Perkin Elmer Company, MA, America). Sample injection was performed in split mode (20:1) into a DB-5MS capillary column (30 m × 25 mm × 0.25 µm). Helium was used as the carrier gas at 1 mL/min. The GC injector temperature was set at 250 °C. The oven temperature program was optimized to hold at 50 °C for 2 min), finally increasing by 50 °C/min up to 250 °C (maintained for 2 min). The transfer line temperature was adjusted to 250 °C. Mass spectrometry conditions were as follows: electron ionization source set to 70 eV, MS transmission line to 250 °C, and MS source to 230 °C. The mass spectrometer was run in full-scan mode (*m/z* 45--550). The essential oil production was analyzed by peak area.

The essential compounds were identified on the basis of a comparison of their retention index (RI) relative to *n*-alkanes (C8--C20), standard substance, as well as published data and EI mass spectra from the literature. The relative mass fraction of the *M. bracteata* EO was calculated using the peak area normalization method.

The formula for the retention index (RI) is shown in Equation (1) \[[@B35-ijms-20-05696],[@B36-ijms-20-05696]\]: where Z is the number of carbons© in the smaller alkane; RT(x) is the retention time of the unknown compound; RT(z) is the retention time of the smaller alkane; and RT(Z + 1) is the retention time of the larger alkane.

4.3. Determination of Antimicrobial Activity and MIC of *M. bracteata* EO {#sec4dot3-ijms-20-05696}
-------------------------------------------------------------------------

The test strains, *D. dadantii* Onc5, *S. aureus* ATCC25933, *Pseudomonas* spp., *E. coli* ATCC25922, *S. marcescens* MG1, *P. aeruginosa* PAO1, and *C. violaceum*, were cultured in LB broth at 150 rpm and 30 °C for 12 h. All of the tested strains were adjusted to a microbial suspension of 10^9^ CFU/mL with distilled water. The *M. bracteata* EO was serially diluted to 80‰, 40‰, 20‰, and 10‰ with methanol. The plate perforation method was performed using the following procedure with some modifications \[[@B37-ijms-20-05696]\]. Briefly, 1% test bacterial suspension (10^9^ CFU/mL) was added to the heated LB medium (containing 2% agar) at a temperature of 50 °C. After blending, the mixture was quickly poured into the Petri dishes. Then, 6-mm holes were punched in the solidified LB medium in the Petri dishes. A 35-µL volume of *M. bracteata* EO at different concentrations (80‰, 40‰, 20‰, and 10‰) was added to the holes. The culture plates were incubated at 30 °C. The antimicrobial activity was determined by measuring the antimicrobial diameters. Methanol and kanamycin (250 µg/mL) solutions was used as the negative control and positive control, respectively.

Double dilution method was applied to test the minimum inhibitory concentrations (MICs) of *M. bracteata* EO. The assay was performed using 1.5-mL microcentrifuge tubes and consisted of a gradient of *M. bracteata* EO---80‰, 40‰, 20‰, 10‰, 5‰, 2.5‰, 1.25‰, and 0.625‰---with the same final volume (150 μL), and 150 μL of bacterial suspension (1% of tested bacteria (OD600, 0.9) were added to LB medium). After mixing, the tubes were incubated at 30 °C and 150 rpm for 24 h and the OD600 was measured. Each assay was performed in triplicate.

4.4. Quorum Sensing Inhibition Assays {#sec4dot4-ijms-20-05696}
-------------------------------------

The QSI assay was performed on agar plates employing the biosensor strain *C. violaceum* CV026, which produces a purple pigment only in response to added exogenous AHLs \[[@B38-ijms-20-05696]\].

The quorum sensing inhibition assay was performed according to the procedure described by Zhang et al. \[[@B39-ijms-20-05696]\], with some modifications. An overnight culture of 1% CV026 was spread on LB plates (20 mL), and then exogenous C6-HSL solution was added to the plates. Filter paper (6 mm in diameter) was then placed on the center of the plate. Next, 15 µL of the *M. bracteata* EO and methyleugenol (ME) was added to filter paper, and the plates were incubated for 24 h at 30 °C. QSI was assessed from the formation of a ring of inhibition, as a result of violacein production, around the filter paper.

4.5. Growth Curve Analysis {#sec4dot5-ijms-20-05696}
--------------------------

The 1% *C. violaceum* (OD600, 0.9) was incubated in a 250 mL Erlenmeyer flask containing 20 mL of LB broth supplemented with *M. bracteata* EO (sub-MICs, 6% *v*/*v*), and the culture was mixed at 30 °C with shaking at 150 rpm in a rotatory shaker. The growth of bacteria was determined by UV--Visible spectrophotometry (U-290, Hitachi Company, Tokyo, Japan ) at OD600 from 0 to 72 h.

4.6. Violacein Detection Assay {#sec4dot6-ijms-20-05696}
------------------------------

Overnight culture of 1% *C. violaceum* (OD600, 0.9) was added into a glass tube containing 5 mL LB broth supplemented with *M. bracteata* EO (sub-MICs, 6% *v*/*v*), and the liquid was mixed and incubated at 30 °C for 12 h. The specific methods were as follows: 1 mL of the cultured solution was centrifuged in a 1.5 mL centrifuge tube at 4 °C and 12,000× *g* for 20 min; the bacteria and violacein were collected, and 1 mL of dimethyl sulfoxide (DMSO) was added to the centrifuge tube. The mixed liquid was vortexed at room temperature and centrifuged again for 3 min to obtain a purple-colored solution, and the violacein inhibition was measured by UV--Visible spectrophotometry at OD595. Each assay was performed in triplicate.

4.7. Effect of Essential Oil on Biofilm Development {#sec4dot7-ijms-20-05696}
---------------------------------------------------

The effect of *M. bracteata* EO on biofilm was assessed by staining and quantifying the biofilm biomass using a microtiter dish with crystal violet (CV), as previously described \[[@B40-ijms-20-05696]\]. The biofilm biomass was quantified by measuring the absorbance at 550 nm in a microplate reader and recording the absorbance of CV dye bound to the biofilm. Each assay was performed in eight replicates.

To determine the ability of *M. bracteata* EO to disrupt the biofilm, a biofilm disruption assay was performed by following the revised method described previously \[[@B27-ijms-20-05696]\]. Briefly, the test pathogens treated with different concentrations of EO (sub-MICs) were developed in six-well plates with cover glasses 1 cm × 1cm for 12 h, and the biofilms were stained with crystal violet. Then, the biofilm was observed under a light microscope (Bimuyiqi Company, Shanghai, China).

4.8. Swarming Motility {#sec4dot8-ijms-20-05696}
----------------------

An effort was made to examine the effects of *M. bracteata* EO on the swarming motility in *C. violaceum*. The specific method is described briefly as follows \[[@B27-ijms-20-05696]\]. First, 5 μL of overnight bacterial cultured bacterium (OD600, 0.9) was placed on 6-mm filter paper at the center of a plate containing swarming motility medium supplemented with *M. bracteata* EO (sub-MICs, 6% *v*/*v*) and incubated. The ability of swarming motility was measured by the migration distance.

4.9. Extraction and Detection of AHL {#sec4dot9-ijms-20-05696}
------------------------------------

The AHL production was obtained from bacterial culture supernatant using acidified ethyl acetate (0.1% glacial acetic acid in ethyl acetate) as previously described \[[@B41-ijms-20-05696]\]. Cell-free supernatants were centrifugated at 12,000× *g* for 15 min and extracted with acidified ethyl acetate (0.1% glacial acetic acid in ethyl acetate) three times. The AHL extracts were concentrated by rotary evaporation. The AHL extracts were prepared for further assay.

The detection of AHL was determined by the CV026 biosensor and GC. The qualitative assay was performed following the methods of Joshi et al. \[[@B42-ijms-20-05696]\] with some modifications. Briefly, agar plates were prepared by adding an overnight culture of the CV026 biosensor (1%) to the LB medium containing 0.4% agar supplemented with 100 µg/mL kanamycin. Then, 6-mm holes were punched into the agar, which were filled with the 50 µL AHL extracts. The test plates were incubated at 30 °C for 24 h. The AHL production was monitored by the size of diameter of the violacein. The experiments were replicated three times. For quantitative analysis, the C6-HSL was determined using a GC system (Acme 6100 GC, Korea YoungLin, Beijing, China) with a flame ionization detector (FID), both of which were controlled by a computer equipped with Autochro-2000 Chromatography Data System software (YoungLin, Korea). Sample (AHL extracts) injection was performed in split mode (20:1) into an HP-5MS capillary column (30 m × 25 mm × 0.25 µm). Hydrogen was used as the carrier gas at 1 mL/min. The GC injector temperature was set at 200 °C. The oven temperature program was optimized to hold at 100 °C for 1 min and then increased by 25 °C/min up to 280 °C. A standard curve was made with different concentrations of the C6-HSL standard and its corresponding peak areas. Then the C6-HSL concentration in *C. violaceum* was analyzed quantitatively.

4.10. Effect of *M. bracteata* EO on Signaling Molecules (C6-AHL) {#sec4dot10-ijms-20-05696}
-----------------------------------------------------------------

The *C. violaceum* (1%, OD600, 0.9) was grown in 20 mL LB broth with or without EO (sub-MICs, 6% *v*/*v*) for 12 h at 30 °C and 150 rpm. Then, C6-HSL extracts were prepared for further assay by GC and CV026 biosensor.

In order to study the potential degradation of C6-HSL by *M. bracteata* EO, a known synthetic standard (C6-HSL) was added to 20 mL of LB broth untreated and treated with *M. bracteata* EO (sub-MICs, 6% *v*/*v*) and incubated for 0, 6, 12, and 24 h. The C6-HSL concentration was detected by GC.

The CV026 was grown in 20 mL of LB broth for 12 h with or without *M. bracteata* EO (sub-MICs, 6% *v*/*v*) supplemented with the exogenous C6-HSL. The C6-HSL extracts were prepared for further assay by GC.

4.11. Gene Expression Analysis {#sec4dot11-ijms-20-05696}
------------------------------

RT-qPCR was used to monitor the expression of QS genes of *C. violaceum*. The primers, which were used to amplify the *cviI*, *cviR* and other QS-regulated genes, are shown in [Table S1](#app1-ijms-20-05696){ref-type="app"}. A total of 1% *C. violaceum* (OD600, 0.9) was used to incubate 20 mL of LB with or without a range of *M. bracteata* EO concentrations (sub-MICs, 6% *v*/*v*). Cultures were grown for 12 h, the cells were harvested by centrifugation (12,000× *g*, 2 min), and supernatants were discarded. Total RNA was extracted using an RNAprep Pure Cell/Bacteria Kit (Code No. DP430, TIANGEN, Beijing, China). The RNA was used for reverse-transcription using Transcript One-step gDNA Removal and cDNA Synthesis SuperMix (Transgen, Beijing, China). Quantitative RT-qPCR was performed using Real-time PCR Master Mix SYBR Green (Transgen, China) in a Bio-Rad C1000 Manager sequence detector system. The conditions were as follows: two steps of 30 s at 94 °C and 40 cycles of 94 °C for 5 s, 60 °C for 30 s. The calculated cycle threshold (CT) of each gene was normalized to the CT for *rpoD* amplified from the corresponding sample. The RT-qPCR was performed in a LightCycler 96. Fold changes in gene expression were calculated according the 2^−ΔΔCT^ method.

4.12. Statistical Analysis {#sec4dot12-ijms-20-05696}
--------------------------

All experiments were performed at least in triplicate and all data were analyzed by SPSS 19.0 software and presented as the mean values. Differences with *p* \< 0.05 were considered statistically significant.

5. Conclusions {#sec5-ijms-20-05696}
==============

A total of 29 components were identified in *M. bracteata* EO, accounting for 96.49% of the total contents, among which methyleugenol displayed the largest proportion (90.46%), followed by methyl cinnamate (4.25%), and the relative content of other components was less than 1%.

The *M. bracteata* EO demonstrated significant inhibitory effects against seven pathogens, including *Dickeya dadantii* Onc5, *Staphylococcus aureus* ATCC25933, *Pseudomonas* spp., *Escherichia coli* ATCC25922, *Serratia marcescens* MG1, *Pseudomonas aeruginosa* PAO1, and *C. violaceum* ATCC31532. *S. aureus* ATCC25933 and *S. marcescens* MG1 had the highest sensitivity to *M. bracteata* EO, while *P. aeruginosa* PAO1 displayed the strongest resistance to *M. bracteata* EO.

The MIC of *M. bracteata* EO against *C. violaceum* was 10‰. The *M. bracteata* EO also interfered with the QS phenotype behaviors of *C. violaceum* without inhibiting its growth, primarily as follows: the violacein and biofilm were reduced with the maximum of inhibition rates of 85.47% and 75.56%, respectively. Biofilm formation and the swarming movement of *C. violaceum* were also inhibited after treatment with *M. bracteata* EO. The data showed that *M. bracteata* EO was capable of directly degrading C6-HSL and inhibiting the C6-HSL production. Furthermore, treatment with *M. bracteata* EO significantly repressed QS gene expression at sub-MIC concentrations.

Collectively, the anti-QS activity observed here lays a foundation for the development of *M. bracteata* EO into a new QS-inhibitor to prevent and control bacterial contamination. Further study of the interaction mechanism between the components of *M. bracteata* EO and bacteria should be analyzed in detail.

Supplementary materials can be found at <https://www.mdpi.com/1422-0067/20/22/5696/s1>.

###### 

Click here for additional data file.
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![The GC-MS total ion chromatogram of *Melaleuca bracteata* essential oil (EO).](ijms-20-05696-g001){#ijms-20-05696-f001}

![Quorum sensing inhibition (QSI) effect of *M. bracteata* EO on biosensor CV026.](ijms-20-05696-g002){#ijms-20-05696-f002}

![Effect of *M. bracteata* EO on the growth of *Chromobacterium violaceum*. Growth curves of *C. violaceum* treated with varying concentrations of EO: 5‰, 2.5‰, 1.25‰, and 0.625‰ (the control had no *M. bracteata* EO).](ijms-20-05696-g003){#ijms-20-05696-f003}

![(**A**) Effect of *M. bracteata* EO on violacein in *C. violaceum*. (**B**) Quantitative analysis of violacein inhibition in *C. violaceum* by EO (5‰, 2.5‰, 1.25‰, and 0.625‰). Mean values of triplicate independent experiments and SD are shown. Bars indicate standard errors and different letters (a--c) above the bars represent significant differences (*p* \< 0.05).](ijms-20-05696-g004){#ijms-20-05696-f004}

![*M. bracteata* EO reduced biofilm formation of *C. violaceum*. (**A**) Quantitative assessment of biofilm biomass inhibition. Mean values of eight independent experiments and SD are shown. Bars indicate standard errors and different letters (a--c) above the bars represent significant differences (*p* \< 0.05). (**B**) Light microscope images (a--e) under a light microscope at a magnification of 40×. a: untreated; b: 5‰; c: 2.5‰; d: 1.25‰; e: 0.625‰. The arrows indicate the dyed biofilm.](ijms-20-05696-g005){#ijms-20-05696-f005}

![Effect of *M. bracteata* EO at different concentrations (5‰, 2.5‰, 1.25‰ and 0.625‰) on the swarming motility of *C. violaceum*. **a**: control, untreated with EO. **b**--**e**: treated with EO concentrations of 5‰, 2.5‰, 1.25‰, and 0.625‰.](ijms-20-05696-g006){#ijms-20-05696-f006}

![(**A**) Effect of *M. bracteata* EO at different concentrations (5‰, 2.5‰, 1.25‰ and 0.625‰) on C6-HSL of *C. violaceum*. (**B**) Effect of *M. bracteata* EO (5‰) on C6-HSL treated for 0, 6, 12, and 24 h. The degradation of *N*-hexanoyl-[l]{.smallcaps}-homoserine lactone (C6-HSL) was 34.44% at 12 h. (**C**) Effect of *M. bracteata* EO at different concentrations (5‰, 2.5‰, 1.25‰, and 0.625‰) on C6-HSL of *C. violaceum* CV026. The results are the mean (*n* = 3) ± standard deviation. Bars indicate standard errors and different letters (a--c) above the bars represent significant differences (*p* \< 0.05).](ijms-20-05696-g007){#ijms-20-05696-f007}

![Effect of *M. bracteata* EO on the expression of *cviI* and *cviR*. Expression of the house-keeping gene *rpoD* was used as the internal control for each sample. Bars indicate standard errors and different letters (a--c) above the bars represent significant differences (*p* \< 0.05).](ijms-20-05696-g008){#ijms-20-05696-f008}

![Effect of *M. bracteata EO* on the expression of genes regulated by LuxI--LuxR system. *vioA, vioB, vioC, vioD, vioE, hmsN, hmsR, lasA, lasB, hcnB, pilE1*, and *pilE3* were detected in response to *M. bracteata* EO treatment. Expression of the house-keeping gene rpoD was used as the internal control for each sample. The *M. bracteata* EO treatment concentrations were 5‰, 2.5‰, 1.25‰, and 0.625‰. Control was untreated. Bars indicate standard errors, and different letters (a--c) above the bars represent significant differences (*p* \< 0.05).](ijms-20-05696-g009){#ijms-20-05696-f009}
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###### 

Chemical composition of volatile compounds in the *M. bracteata* EO.

  NO.   Compounds Name                                               Molecular Formula   Molecular Weight   Relative Content   Retention Time/min   Retention Index
  ----- ------------------------------------------------------------ ------------------- ------------------ ------------------ -------------------- -----------------
  1     Methyleugenol                                                C~11~H~14~O~2~      178.23             90.46%             29.472               1399
  2     Methyl trans-cinnamate                                       C~10~H~10~O~2~      162.1852           4.25%              28.864               1382
  3     Estragole                                                    C~10~H~12~O         148.2              0.32%              21.064               1194
  4     alpha-Terpineol                                              C~10~H~18~O         154.25             0.23%              20.905               1190
  5     3,7-Dimethyl-1,6-octadien-3-yl acetate 3,7 2-aminobenzoate   C~17~H~23~NO~2~     273.37             0.22%              16.42                1098
  6     2,7-Dimethyl-2,6-octadien-1-ol                               C~10~H~18~O         154.2493           0.18%              23.219               1240
  7     Citronellol                                                  C~10~H~20~O         156.27             0.14%              22.719               1229
  8     2,2-Dimethoxybutane                                          C~6~H~14~O~2~       118.17             0.06%              3.626                \-
  9     3-Hexen-1-ol                                                 C~6~H~12~O          100.16             0.05%              5.735                838
  10    Z-Methyl geranate                                            C~11~H~18~O~2~      182.26             0.05%              26.75                1321
  11    Myrcene                                                      C~10~H~16~          136.23             0.05%              23.411               1244
  12    Elemicin                                                     C~12~H~16~O~3~      208.25             0.04%              33.566               1544
  13    Citral                                                       C~10~H~16~O         152.23             0.04%              24.591               1269
  14    Terpinen-4-ol                                                C~10~H~18~O         154.25             0.03%              20.159               1175
  15    Methyl propionate                                            C~4~H~8~O~2~        88.11              0.03%              2.154                \-
  16    Espatulenol                                                  C~15~H~24~O         220.3505           0.03%              34.417               1575
  17    (3aS,3bR,4S,7R,7aR)-7-methyl-3                               C~15~H~24~          204.3511           0.03%              31.836               1481
  18    Methyl 3,4,5-trimethoxybenzoate                              C~11~H~14~O~5~      226.23             0.03%              36.955               1718
  19    4-epi-cubedol                                                C~15~H~26~O         222                0.03%              36.201               1664
  20    epi-a-Cadinol                                                C~15~H~26~O         222.3663           0.03%              36.368               1673
  21    (R)-Lavandulyl acetate                                       C~12~H~20~O~2~      196                0.02%              21.881               1211
  22    1,3,8-p-Menthatriene                                         C~10~H~14~          134.2182           0.02%              12.847               1100
  23    2-Carene(7CI,8CI)                                            C~10~H~16~          136.234            0.02%              15.707               1083
  24    Methyl butyrate                                              C~5~H~10~O~2~       102.13             0.02%              3.038                \-
  25    Decane                                                       C~10~H~22~          142.28             0.02%              11.826               999
  26    Dispiro\[2.0.2.5\]undecane, 8-methylene                      C~12~H~18~          162.27132          0.02%              23.878               1254
  27    Copaene(6CI)                                                 C~15~H~24~          204.3511           0.02%              32.245               1495
  28    2-(4-Methylphenyl)propan-2-ol                                C~10~H~14~O         150.22             0.02%              20.484               1182
  29    trans-α-Bergamotene                                          C~15~H~24~          204.35106          0.02%              23.382               1243
        Total                                                                                               96.49%                                  
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###### 

Antibacterial activities of *M. bracteata* EO.

  Bacterial Strains                       Concentration/Antimicrobial Diameters (mm)                         MIC                                                                        
  --------------------------------------- -------------------------------------------- --------------------- ----------------------- -------------------- ------------- --------------- ------
  *Dickeya dadantii* Onc5                 11.89 ± 0.246 ^ah^                           10.70 ± 0.291 ^abg^   10.03 ± 0.303 ^bcfgh^   9.00 ± 0.518 ^cfg^   6.00 ± 0.00   20.21 ± 0.11    10‰
  *Staphylococcus aureus* ATCC25933       15.28 ± 1.083 ^ae^                           13.05 ± 0.323 ^be^    10.98 ± 0.520 ^cef^     9.21 ± 0.078 ^def^   6.00 ± 0.00   26.01 ± 0.131   2.5‰
  *Escherichia coli* ATCC25922            11.38 ± 0.286 ^ai^                           10.15 ± 0.451 ^bgh^   9.325 ± 0.343 ^bh^      8.33 ± 0.354 ^cgh^   6.00 ± 0.00   18.78 ± 1.032   10‰
  *Pseudomonas aeruginosa* PAO1           10.47 ± 0.186 ^aj^                           9.82 ± 0.279 ^bh^     9.45 ± 0.236 ^ch^       8.15 ± 0.193 ^dh^    6.00 ± 0.00   17.23 ± 0.187   20‰
  *Serratia marcescens* MG1               14.11 ± 0.789 ^af^                           11.81 ± 0.363 ^bf^    10.57 ± 0.191 ^cefg^    9.87 ± 0.484 ^de^    6.00 ± 0.00   25.08 ± 1.31    2.5‰
  *Pseudomonas* spp.                      13.42 ± 0.715 ^ag^                           12.49 ± 0.308 ^bef^   11.50 ± 0.236 ^ce^      9.69 ± 0.315 ^def^   6.00 ± 0.00   23.17 ± 0.33    5‰
  *Chromobacterium violaceum* ATCC31532   11.55 ± 0.34 ^ai^                            10.86 ± 0.49 ^ag^     9.80 ± 0.27 ^bgh^       8.03 ± 0.26 ^ch^     6.00 ± 0.00   21.61 ± 1.029   10‰

Note: Different letters (a--d) within the same row represent significant differences at the different concentrations (*p* \< 0.05). Different letters (e--j) within the same line represent significant differences at the different concentrations (*p* \< 0.05).
